Pharmacokinetic evaluation of linezolid in patients with major thermal injuries
Open Access
- 15 January 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 63 (3), 553-559
- https://doi.org/10.1093/jac/dkn541
Abstract
To evaluate the pharmacokinetics of linezolid following its administration in patients with major thermal injuries and in a group of healthy volunteers. In an open-label, multicentre design with two parallel groups, a group of patients with major thermal injuries (>20% body area) and a group of age-, sex- and weight-matched healthy volunteers, subjects received a single 600 mg intravenous dose of linezolid. Serial blood and urine collections were made and the concentrations of linezolid in these samples were determined by HPLC. Non-compartmental analyses were used to describe the pharmacokinetic disposition of linezolid. Cmax concentrations and the volume of distribution at steady state (Vss) were not statistically different (P > 0.05) between the two groups of subjects. In contrast, values describing clearance [elimination rate constant (kel), t1/2 and mean residence time (MRT)] were significantly different (P < 0.05) in patients with thermal injuries compared with volunteers, which lead to an approximate reduction by half in AUC0–∞ from 98.1 mg·h/L (volunteers) to 42.5 mg·h/L (patients). Although renal clearance was similar in the two groups (24.7 ± 23 versus 30.6 ± 14.3 mL/min; P = 0.156), non-renal clearance was substantially increased (323 ± 191 versus 80.4 ± 27.5 mL/min) in the patients with thermal injuries, though this difference did not achieve statistical significance (P = 0.063). The pharmacokinetics of linezolid are altered in patients with major thermal injuries, mainly as a result of increased non-renal clearance. These changes are of sufficient magnitude that linezolid concentrations may be sub-therapeutic in some patients and we suggest that the dosage interval may need to be decreased in this patient population.This publication has 21 references indexed in Scilit:
- Pharmacokinetic Evaluation of Single-Dose Intravenous Daptomycin in Patients with Thermal Burn InjuryAntimicrobial Agents and Chemotherapy, 2008
- Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of NephrotoxicityAntimicrobial Agents and Chemotherapy, 2008
- Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in BrazilClinical Microbiology & Infection, 2008
- Linezolid: effectiveness and safety for approved and off-label indicationsExpert Opinion on Pharmacotherapy, 2007
- Pharmacokinetic/Pharmacodynamic Factors Influencing Emergence of Resistance to Linezolid in an In Vitro ModelAntimicrobial Agents and Chemotherapy, 2007
- Quality Assurance Assessment of the Use of Linezolid in the Treatment of Thermal Injury Patients at a Community Teaching HospitalJournal of Burn Care & Research, 2007
- Linezolid Pharmacokinetics in Adult Patients with Cystic FibrosisAntimicrobial Agents and Chemotherapy, 2004
- Occurrence of MRSA Endocarditis During Linezolid TreatmentEuropean Journal of Clinical Microbiology & Infectious Diseases, 2003
- Clinical Pharmacodynamics of Linezolid in Seriously Ill Patients Treated in a Compassionate Use ProgrammeClinical Pharmacokinetics, 2003
- Pharmacokinetics of Systemically Administered Antibiotics in Patients with Thermal InjuryClinical Infectious Diseases, 1992